News

Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year. Still, some companies are performing

Multiple paths to immense wealth exist. A few lucky people win the lottery. Some start successful businesses. Others invest in stocks that deliver explosive gains.

Summit Therapeutics (NASDAQ: SMMT)

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are

AT&T (NYSE: T) stock offers passive income investors a robust dividend yield and the chance for an increasing stock price.

*Stock prices used were the afternoon prices of March 19, 2025. The video

Nvidia (NASDAQ: NVDA) has built a dominant position in one of the highest-growth areas around: artificial intelligence (AI) chips. That has helped it generate enormous levels of revenue, for

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's

NuScale Power (NYSE: SMR) is not an investment for the faint of heart. Indeed, it is losing money today and will probably continue to do so for at least another few years. But if you can handle a

It's not always easy for a member of the U.S. House of Representatives to secure a spot in the limelight. After all, the House has 435 representatives. But certain members of Congress receive plenty

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD) and its various growth opportunities. To learn more, check out the short video, consider subscribing, and click the special offer

Image source: The Motley Fool.

MacroGenics (NASDAQ: MGNX)Q4 2024 Earnings CallMar 20, 2025, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

IonQ (NYSE: IONQ), a very hot stock during the quantum computing bull run late last year and early in 2025, cooled down considerably on Thursday. Investors eagerly traded out of the stock on news

Over the past few days HealthEquity (NASDAQ: HQY) shares have been rather sickly. The health savings account (HSA) specialist's stock was rocked by a disappointing earnings report, and as a result

If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The pharmaceutical giant isn't as risky an investment as it may appear to be. Its

So, you want to invest in AbbVie (NYSE: ABBV) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy

Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (NYSE: PFE) and

Last year, Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical trial results. The company's shares soared in late February

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.

The

Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has

Last year, Summit Therapeutics (NASDAQ: SMMT) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win. Summit's market capitalization of $15.3